Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22916
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDoecke, James D-
dc.contributor.authorWard, Larry-
dc.contributor.authorBurnham, Samantha C-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorLi, Qiao-Xin-
dc.contributor.authorCollins, Steven-
dc.contributor.authorFowler, Christopher J-
dc.contributor.authorManuilova, Ekaterina-
dc.contributor.authorWidmann, Monika-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorMasters, Colin L-
dc.date2020-03-31-
dc.date.accessioned2020-04-14T04:00:52Z-
dc.date.available2020-04-14T04:00:52Z-
dc.date.issued2020-03-31-
dc.identifier.citationAlzheimer's Research & Therapy 2020; 12(1): 36en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22916-
dc.description.abstractβ-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer's disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1-42) (Aβ42), Aβ (1-40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic-area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.en
dc.language.isoeng-
dc.subjectAlzheimer’s diseaseen
dc.subjectBeta-amyloiden
dc.subjectCerebrospinal fluiden
dc.subjectConcordance PETen
dc.subjectTauen
dc.titleElecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging.en
dc.typeJournal Articleen
dc.identifier.journaltitleAlzheimer's Research & Therapyen
dc.identifier.affiliationAustralian E-Health Research Centre, CSIRO, Parkville, Melbourne, Victoria, 3052, Australiaen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine (RMH), The University of Melbourne, Parkville, Melbourne, Victoria, 3052, Australiaen
dc.identifier.affiliationDepartment of Biomedical Sciences, Macquarie University, North Ryde, New South Wales, 2113, Australiaen
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, 6009, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australiaen
dc.identifier.affiliationCooperative Research Council for Mental Health, Melbourne, Victoria, 3052, Australiaen
dc.identifier.affiliationAustralian E-Health Research Centre, CSIRO Health & Biosecurity, Level 5, 901/16 Royal Brisbane & Women's Hospital, Brisbane, Queensland, 4029, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australiaen
dc.identifier.affiliationRoche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germanyen
dc.identifier.affiliationRoche Diagnostics GmbH, Sandhoferstrasse 116, 68305, Mannheim, Germanyen
dc.identifier.doi10.1186/s13195-020-00595-5en
dc.type.contentTexten
dc.identifier.orcid0000-0002-5832-9875en
dc.identifier.pubmedid32234072-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.